(19)
(11) EP 1 632 248 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
29.12.2010 Bulletin 2010/52

(45) Mention of the grant of the patent:
13.10.2010 Bulletin 2010/41

(21) Application number: 05009688.2

(22) Date of filing: 23.08.1996
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
 A61K 38/20(2006.01)

(54)

Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness

Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen

Anticorps Anti-Interleukin-9 ou anticorps du récepteur Anti-Interleukin-9 pour le traitment de la hyper-réponse bronchique

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 24.08.1995 US 2765 P
06.08.1996 US 23800 P

(43) Date of publication of application:
08.03.2006 Bulletin 2006/10

(60) Divisional application:
10004496.5 / 2241329

(62) Application number of the earlier application in accordance with Art. 76 EPC:
96929657.3 / 0846173

(73) Proprietor: LIGAND PHARMACEUTICALS INCORPORATED
La Jolia, CA 92037 (US)

(72) Inventors:
  • Maloy, W. Lee
    Lansdale PA 19446 (US)
  • Kari, Prasad U.
    Lansdale PA 19440 (US)
  • Nicolaides, Nicholas
    Boothwyn PA 19061 (US)

(74) Representative: Graf von Stosch, Andreas 
Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22
80538 München
80538 München (DE)


(56) References cited: : 
EP-A- 0 361 284
 WO-A-92/05698
   
  • RENAULD J-C ET AL: "EXPRESSION CLONING OF THE MURINE AND HUMAN INTERLEUKIN 9 RECEPTOR CDNAS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 89, June 1992 (1992-06), pages 5690-5694, XP002065134 ISSN: 0027-8424
  • RENAULD ET AL: "HUMAN P40/IL-9. EXPRESSION IN ACTIVATED CD4+ T CELLS, GENOMIC ORGANIZATION, AND COMPARISON WITH THE MOUSE GENE" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 144, no. 11, 1 June 1990 (1990-06-01), pages 4235-4241, XP002085431 ISSN: 0022-1767
  • MEYERS D A ET AL: "EVIDENCE FOR A LOCUS REGULATING TOTAL SERUM IGE LEVELS MAPPING TO CHROMOSOME 5" GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 23, no. 2, 15 September 1994 (1994-09-15), pages 464-470, XP000616442 ISSN: 0888-7543
  • HOLGATE S T: "GENETIC AND ENVIRONMENTAL INFLUENCES ON AIRWAY INFLAMMATION IN ASTHMA" INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 107, no. 1/3, 1 May 1995 (1995-05-01), pages 29-33, XP000616471 ISSN: 1018-2438
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).